Long-term proton pump inhibitors use and its association with premalignant gastric lesions: a systematic review and meta-analysis
Frontiers in Pharmacology · 25.08.2023 · 14
DOI: 10.3389/fphar.2023.1244400 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 25.08.2023. Verfasst von Zeyi Zheng und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Traditional Chinese Medicine, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Long-term maintenance therapy with proton pump inhibitors (PPIs) is a common treatment strategy for acid-related gastrointestinal diseases. However, concerns have been raised about the potential increased risk of gastric cancer and related precancerous lesions with long-term PPI use. This systematic review and meta-analysis aimed to evaluate this potential risk.
Methods
We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials for randomised controlled trials published before 1 March 2023, with no language restrictions. The primary endpoint was the occurrence and progression of gastric mucosal atrophy, intestinal metaplasia, Enterochromaffin-like (ECL) cell hyperplasia, gastric polyps, and gastric cancer during the trial and follow-up. Data were analysed using a random effects model.
Results
Of the 4,868 identified studies, 10 met the inclusion criteria and were included in our analysis, comprising 27,283 participants. Compared with other treatments, PPI maintenance therapy for more than 6 months was associated with an increased risk of ECL cell hyperplasia (OR 3.01; 95% CI 1.29 to 7.04; p = 0.01). However, no significant increase was found in the risk of gastric mucosal atrophy (OR 1.01; 95% CI 0.55 to 1.85; p = 0.97), intestinal metaplasia (OR 1.14; 95% CI 0.49 to 2.68; p = 0.76), gastric polyps (OR 1.13; 95% CI 0.68 to 1.89; p = 0.64), or gastric cancer (OR 1.06; 95% CI 0.79 to 1.43; p = 0.71).
Conclusion
This systematic review and meta-analysis does not support an increased risk of gastric cancer or related precancerous lesions with long-term PPI maintenance therapy. However, long-term PPI use should be monitored for potential complications such as ECL cell hyperplasia. Further studies are needed to confirm these findings and evaluate the safety of PPI maintenance therapy for acid-related gastrointestinal diseases. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/ , Identifier: PROSPERO (CRD42022379692).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Traditional Chinese Medicine, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.
- School of Basic Medicine, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.
- School of Water Resources and Hydropower Engineering, Wuhan University, Wuhan, Hubei, China.
Zitieren
APA
Zheng, Z., Lu, Z., & Song, Y. (2023). Long-term proton pump inhibitors use and its association with premalignant gastric lesions: a systematic review and meta-analysis. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1244400
Vancouver
Zheng Z, Lu Z, Song Y. Long-term proton pump inhibitors use and its association with premalignant gastric lesions: a systematic review and meta-analysis. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1244400
BibTeX
@article{Zheng2023,
author = {Zheng, Zeyi and Lu, Ziyu and Song, Yani},
title = {Long-term proton pump inhibitors use and its association with premalignant gastric lesions: a systematic review and meta-analysis},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1244400}
}
EUVIMED